These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15386648)

  • 1. Stochastic league tables: an application to diabetes interventions in the Netherlands.
    Hutubessy RC; Niessen LW; Dijkstra RF; Casparie TF; Rutten FF
    Health Econ; 2005 May; 14(5):445-55. PubMed ID: 15386648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
    Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
    Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables.
    Baltussen RM; Hutubessy RC; Evans DB; Murray CJ
    Int J Technol Assess Health Care; 2002; 18(1):112-9. PubMed ID: 11987434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stochastic league tables: communicating cost-effectiveness results to decision-makers.
    Hutubessy RC; Baltussen RM; Evans DB; Barendregt JJ; Murray CJ
    Health Econ; 2001 Jul; 10(5):473-7. PubMed ID: 11466807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifetime health effects and costs of diabetes treatment.
    Niessen LW; Dijkstra R; Hutubessy R; Rutten GE; Casparie AF
    Neth J Med; 2003 Nov; 61(11):355-64. PubMed ID: 14768718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
    Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
    Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Methods of comparative economic evaluations of therapies and for rational allocation of resources across sectors of health care systems - introduction, advantages, risks].
    Wasem J; Hessel F; Kerim-Sade C
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S12-20. PubMed ID: 11533902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness league tables: valuable guidance for decision makers?
    Mauskopf J; Rutten F; Schonfeld W
    Pharmacoeconomics; 2003; 21(14):991-1000. PubMed ID: 13129413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of diabetes mellitus type 2 in family practice].
    Valk GD; Kriegsman DM; Nijpels G
    Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1536-40. PubMed ID: 11525085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using an economic model of diabetes to evaluate prevention and care strategies in Australia.
    Colagiuri S; Walker AE
    Health Aff (Millwood); 2008; 27(1):256-68. PubMed ID: 18180502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design.
    Sullivan MD; Anderson RT; Aron D; Atkinson HH; Bastien A; Chen GJ; Feeney P; Gafni A; Hwang W; Katz LA; Narayan KM; Nwachuku C; O'Connor PJ; Zhang P;
    Am J Cardiol; 2007 Jun; 99(12A):90i-102i. PubMed ID: 17599429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of cost-effectiveness analysis to multiple products: a practical guide.
    Bala MV; Zarkin GA
    Am J Manag Care; 2002 Mar; 8(3):211-8. PubMed ID: 11915971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals.
    Koopmanschap MA; Stolk EA; Koolman X
    Int J Technol Assess Health Care; 2010 Apr; 26(2):198-204. PubMed ID: 20392324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new approach to assessing the health benefit from obesity interventions in children and adolescents: the assessing cost-effectiveness in obesity project.
    Haby MM; Vos T; Carter R; Moodie M; Markwick A; Magnus A; Tay-Teo KS; Swinburn B
    Int J Obes (Lond); 2006 Oct; 30(10):1463-75. PubMed ID: 17003807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness acceptability curves--caveats quantified.
    Jakubczyk M; Kamiński B
    Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of age on cost-effectiveness ratios and its control in decision making.
    Baltussen R; Leidl R; Ament A
    Health Econ; 1996; 5(3):227-39. PubMed ID: 8817297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.